Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2015 - 2025)

Catalyst Pharmaceuticals (CPRX) reported Gains from Sales and Divestitures of $333865.0 for Q4 2025, down 8.5% on a YoY basis from $364861.0 in Q4 2024, and down 8.5% quarter-over-quarter from $364861.0 in Q4 2024.

Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2015 - 2025) Analysis & Trends

Catalyst Pharmaceuticals has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $333865.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 8.5% year-over-year to $333865.0; the trailing twelve-month figure through Dec 2025 stood at $333865.0 (down 8.5% YoY), and the FY2025 full-year result was $333865.0, down 8.5% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $333865.0, down from $364861.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $364861.0 in Q4 2024, with the low at $333865.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Catalyst Pharmaceuticals 3.84 Bn 3.08 Bn 134.92 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 333,865.00
Dec 31, 2025 333,865.00
Dec 31, 2024 364,861.00
Dec 31, 2024 364,861.00
Dec 31, 2017 26,667.00
Dec 31, 2017 26,667.00
Dec 31, 2016 26,667.00
Dec 31, 2016 26,667.00
Dec 31, 2015 26,666.00
Dec 31, 2015 26,666.00